Transition Bio Analysis: $77M Raised
What is Transition Bio?
Transition Bio combines technology from Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab to create a condensate drug discovery platform. Their platform utilizes droplet microfluidics and cellular imaging to analyze chemical interactions at the molecular level. The company employs machine learning and artificial intelligence to enhance drug discovery processes.
Location
Cambridge, United States
Employees
11-50
Founded
2020
Funding Status
Series A
Product Features & Capabilities
- Condensate drug discovery platform
- Droplet microfluidics technology
- Cellular imaging solutions
- Machine learning optimization for drug discovery
Use Cases
Analyze chemical interactions in condensate systems; Develop small-molecule inhibitors for cancer treatment; Optimize drug candidates using AI; Conduct research in collaboration with academic labs; Present research findings at scientific conferences
Other Considerations
Closed $50 million Series A financing; Presented research at AACR-NCI-EORTC 2025; Leadership team includes experienced executives from biotech
See something that needs updating? Suggest edits to this profile.